International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 10-No.4 (2024) pp. 2372-2381
http://www.ijcesen.com

ISSN: 2149-9144

Research Article

Multidisciplinary Healthcare for Hypothyroidism Contributions from Physicians, Nurses, and Laboratory Professionals in Saudi Arabia

Omar Gharbi T Alenezi[1]*, Alenezi Malek Ramadan A[2], Alanazi Abdulrhman Rikaa M[3], Abdulrazaq Lafi Ayadh Alenezi[4], Omar Ali Jaber Asiri[5], Fayez Khalaf Mashan Alanazi[6], Alghamdi Saad Bakheet M[7], Alruwaili Khairiah Satim E[8], Raghad Fayez Dughayshim Al Anazi[9], Reem Najeb Shetaiwi Aljohane[10]

[1]Pediatric Endocrinologist – Maternity and Children Hospital – Arar, Northern Borders – Saudi Arabia
* **Corresponding Author Email:** ogalenezi@moh.gov.sa- **ORCID:** 0000-0002-0247-7850

[2]General Physician – Northern Borders Health Cluster – Arar, Northern Borders – Saudi Arabia
Email: dmr33@live.com - **ORCID:** 0000-0002-9247-7850

[3]Laboratory Technician – Forensic Services Center, Toxicology Department – Arar, Northern Borders – Saudi Arabia
Email: abralenzi@moh.gov.sa- **ORCID:** 0000-0002-8247-7850

[4]Laboratory Specialist – Medical Supply – Arar, Northern Borders – Saudi Arabia
Email: abdulrazaqa@moh.gov.sa- **ORCID:** 0000-0002-7247-7850

[5]Laboratory Specialist – Aseer Regional Laboratory – Abha, Aseer Region – Saudi Arabia
Email: uarx_007@hotmail.com- **ORCID:** 0000-0002-6247-7850

[6]Laboratory Specialist – Hafar Al-Batin Health Cluster – Hafar Al-Batin, Eastern Region – Saudi Arabia
Email: fayez_8888@hotmail.com- **ORCID:** 0000-0002-4247-7850

[7]Nursing Technician – Medical Administration – Taif, Makkah Region – Saudi Arabia
Email: saadbakhit83@gmail.com - **ORCID:** 0000-0002-3247-7850

[8]Nursing Specialist – Al-Jouf Health Cluster – Sakaka, Al-Jouf – Saudi Arabia
Email: khairiaha@moh.gov.sa- **ORCID:** 0000-0002-2247-7850

[9]Nursing Specialist – Turaif General Hospital – Turaif, Northern Borders – Saudi Arabia
Email: rfalenazi@moh.gov.sa- **ORCID:** 0000-0002-1247-7850

[10]Nursing Technician – Al-Masjid Health Center – Al Madinah, Al Madinah Region – Saudi Arabia
Email: ree2m@mail.com - **ORCID:** 0000-0002-0247-7850

Article Info:

DOI: 10.22399/ijcesen.4029
Received : 01 November 2024
Accepted : 22 December 2024

Keywords

Hypothyroidism,
multidisciplinary healthcare,
physicians,
nurses,
laboratory professionals,
Saudi Arabia

Abstract:

Hypothyroidism, a common endocrine disorder characterized by insufficient production of thyroid hormones, necessitates collaborative efforts among healthcare professionals to ensure effective diagnosis, management, and patient education. In Saudi Arabia, the approach to treating hypothyroidism leverages a multidisciplinary healthcare model that includes physicians, nurses, and laboratory professionals. Physicians, particularly endocrinologists and general practitioners, play a pivotal role in diagnosing the condition through regular screenings and clinical assessments. They are also responsible for formulating treatment plans that may involve hormone replacement therapies and ongoing monitoring. Nurses contribute significantly to patient care by providing education on medication adherence, lifestyle modifications, and the importance of regular follow-ups, thus ensuring that patients are actively involved in their own health management. Laboratory professionals serve as essential members of the healthcare team by conducting comprehensive thyroid function tests that are critical for accurate diagnosis and ongoing monitoring of hypothyroidism. Their expertise enables timely and precise analysis of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels, which are crucial for adjusting treatment protocols. In the context of Saudi Arabia, where healthcare systems are continuously evolving, the collaboration among these professionals helps address the growing prevalence of thyroid disorders.

Emphasizing a team-based approach not only enhances patient outcomes but also fosters an integrated healthcare system that benefits from shared knowledge and resources. The contributions of each discipline are vital, culminating in a holistic strategy that not only treats hypothyroidism but empowers patients to lead healthier lives.

1. Introduction

Hypothyroidism, characterized by a deficiency of thyroid hormone, stands as one of the most prevalent endocrine disorders worldwide, with a significant and growing impact on the population of the Kingdom of Saudi Arabia. This chronic condition, if undiagnosed or suboptimally managed, can lead to a vast spectrum of debilitating consequences, ranging from fatigue, weight gain, and cognitive impairment to more severe cardiovascular complications, dyslipidemia, and compromised quality of life [1].

The burden of thyroid disorders in Saudi Arabia is substantial and appears to be evolving. Early studies indicated a lower prevalence of overt hypothyroidism compared to Western countries, but recent data suggest a changing landscape, likely influenced by genetic factors, improved screening, and shifts in environmental determinants such as iodine status. A large, recent national study in Saudi Arabia reported the overall prevalence of thyroid dysfunction to be as high as 11.8%, with hypothyroidism constituting a significant portion of these cases. Subclinical hypothyroidism, a condition with its own set of controversies regarding management, is particularly common, especially among women and the elderly [1]. Another pivotal study focusing on the Saudi population found that Hashimoto's thyroiditis, an autoimmune disorder and the leading cause of hypothyroidism in iodine-sufficient areas, is a predominant etiology, highlighting the need for autoimmune workup in the diagnostic process [2]. The economic and societal burden is equally noteworthy, as untreated or poorly controlled hypothyroidism contributes to decreased workplace productivity, increased healthcare utilization, and a significant strain on the healthcare system.

Traditionally, the management of hypothyroidism has been perceived as the sole responsibility of the endocrinologist or, in many cases, the primary care physician. The physician's role is undeniably central and multifaceted. It begins with the crucial task of clinical suspicion and accurate diagnosis, synthesizing patient symptoms with biochemical evidence. The physician interprets thyroid function tests (TSH, Free T4), orders additional investigations like anti-thyroid peroxidase (anti-TPO) antibodies to ascertain the etiology, initiates and titrates levothyroxine therapy, and monitors for adequacy of treatment and potential complications [3]. This requires a deep understanding of the physiological nuances, such as the impact of pregnancy, other medications, and comorbid conditions on thyroid hormone requirements.

However, the limitations of a purely physician-centric model are increasingly apparent in the management of a chronic condition like hypothyroidism. Physicians, particularly in busy clinics, often lack the time to provide the extensive education, ongoing counseling, and day-to-day support that patients require. This is where the indispensable role of other healthcare professionals emerges. The **nurse**, especially specialized diabetes and endocrine nurses, acts as a critical bridge between the physician's treatment plan and the patient's lived experience. Nurses are instrumental in providing structured patient education on the nature of the disease, the importance of lifelong adherence, and the correct way to take levothyroxine (e.g., on an empty stomach, avoiding interactions with calcium and iron supplements) [4]. They are often the first point of contact for patients, addressing concerns, managing side effects, and providing motivational support to overcome barriers to adherence. Furthermore, nurses play a vital role in screening for hypothyroidism in high-risk populations and monitoring for signs of myxedema coma, a rare but life-threatening complication.

The foundation upon which all diagnosis and management decisions are made is the laboratory data. The contributions of **laboratory professionals**—from phlebotomists to clinical biochemists—are fundamental to the quality of hypothyroidism care. The accuracy and precision of Thyroid-Stimulating Hormone (TSH) assays are paramount, as TSH is the most sensitive and specific marker for primary hypothyroidism. Laboratory professionals ensure the reliability of these tests through rigorous quality control, standardization of assays, and accurate reporting [5]. They are also responsible for communicating critical values and understanding potential assay interferences that could lead to misdiagnosis. In the context of Saudi Arabia, where the establishment of region-specific reference ranges is crucial due to potential ethnic and environmental variations, the role of laboratory medicine in conducting population-specific studies is of paramount importance [6].

The Saudi healthcare system, with its ongoing transformational journey under Vision 2030, provides a unique context for implementing and studying multidisciplinary care models. The vision emphasizes quality, efficiency, and patient-centered care, all of which are embodied in a team-based approach to chronic disease management [7]. While specialist centers in major cities may have access to endocrinologists, diabetes educators, and advanced laboratories, disparities in care may exist in remote regions. This underscores the necessity of a well-defined, collaborative framework that can be standardized across the Kingdom. A multidisciplinary team (MDT) for hypothyroidism, integrating physicians, nurses, and laboratory professionals, can streamline the patient journey from suspicion to diagnosis, treatment initiation, and long-term follow-up, ensuring consistency and excellence in care delivery.

Evidence strongly supports the efficacy of such collaborative models. Studies have demonstrated that nurse-led interventions in chronic disease management, including thyroid disorders, lead to improved patient knowledge, better medication adherence, and higher satisfaction rates [8]. Furthermore, close collaboration between clinicians and laboratory professionals reduces diagnostic errors and ensures appropriate test utilization [9]. In the specific context of Saudi Arabia, research has begun to highlight the positive outcomes of collaborative care models in other chronic diseases like diabetes, suggesting a ready framework that could be adapted for hypothyroidism [10]. However, challenges such as professional role boundaries, communication gaps, and the need for interprofessional education must be addressed to realize the full potential of this team-based approach [11].

This research paper will, therefore, delve into the critical components of multidisciplinary healthcare for hypothyroidism within the Saudi context. It will critically analyze the distinct yet complementary roles of physicians, nurses, and laboratory professionals. The paper will also evaluate the impact of this collaborative model on key patient outcomes, including biochemical control, symptom resolution, quality of life, and healthcare efficiency. Finally, it will discuss the opportunities and barriers to implementing such a model across the diverse healthcare landscape of Saudi Arabia, proposing a framework for a truly integrated, patient-centered approach to managing this common and impactful endocrine disorder [12].

2. Hypothyroidism in Saudi Arabia:

The Kingdom of Saudi Arabia presents a distinctive and evolving epidemiological landscape for thyroid disorders, characterized by a significant and rising burden of hypothyroidism that demands a nuanced understanding of its underlying causes. Historically, the prevalence of thyroid dysfunction in the region was perceived to be lower than in Western and iodine-sufficient countries. However, a surge in recent, robust epidemiological studies reveals a different and more concerning picture, painting hypothyroidism as a common endocrine ailment with substantial implications for public health policy and clinical practice. This shift is attributed not only to improved diagnostic capabilities and heightened clinical awareness but also to a complex interplay of genetic, autoimmune, and environmental factors unique to the Saudi population [13].

The scale of the problem is substantial. A comprehensive systematic review and meta-analysis focusing specifically on the Gulf Cooperation Council (GCC) countries, with a heavy weighting on Saudi data, estimated the pooled prevalence of hypothyroidism to be 9.5%. This figure is significantly higher than previous local estimates and begins to approach rates observed in Western nations, indicating a pressing health issue [13]. When dissected by subtype, subclinical hypothyroidism (SCH) emerges as the most frequent form, with a prevalence ranging from 6% to 8% in adult populations. SCH, defined by an elevated Thyroid-Stimulating Hormone (TSH) level with a normal Free Thyroxine (FT4), is a clinical entity of great importance. While often asymptomatic, it is associated with an increased risk of progression to overt hypothyroidism, as well as potential adverse effects on lipid metabolism and cardiovascular health, thereby representing a large pool of individuals requiring monitoring and, in some cases, intervention [14]. The prevalence of overt hypothyroidism, while lower at approximately 2-3%, carries a more immediate and severe burden of morbidity, necessitating lifelong treatment.

A critical factor shaping the etiology of hypothyroidism in Saudi Arabia is the high prevalence of autoimmune thyroid disease (AITD), particularly Hashimoto's thyroiditis. Numerous hospital-based and population studies have consistently identified autoimmunity as the leading cause of both overt and subclinical hypothyroidism in the Kingdom. One pivotal study conducted in the central region found that anti-Thyroid Peroxidase (anti-TPO) antibodies were positive in over 80% of patients diagnosed with overt hypothyroidism, underscoring the dominant role of autoimmune destruction [15]. This high prevalence of

Hashimoto's has significant clinical implications. It suggests that a one-time etiological workup, including anti-TPO antibodies, is highly valuable in the Saudi context, as it can confirm the cause, provide prognostic information regarding the risk of progression, and often eliminate the need for repeated investigations.

The role of iodine status in the Saudi context is a topic of particular interest and has undergone a dramatic transformation. Iodine deficiency was once a significant public health problem in the region and a classic cause of hypothyroidism and goiter. However, the mandatory iodization of salt, implemented as a national policy, has been largely successful in correcting this deficiency. Recent surveys indicate that Saudi Arabia is now an iodine-sufficient country, with median urinary iodine concentrations within the optimal range for school-aged children and pregnant women [16]. This public health success story has consequently shifted the etiological spectrum away from iodine-deficiency-related goiter and towards autoimmune-mediated hypothyroidism, mirroring the pattern seen in other iodine-replete parts of the world. However, the "double-edged sword" of iodine sufficiency must be acknowledged; while it prevents deficiency disorders, it may also unmask or potentially exacerbate underlying autoimmune thyroiditis in genetically susceptible individuals, which may partly explain the rising prevalence of Hashimoto's in the population.

Demographic disparities in the prevalence of hypothyroidism within Saudi Arabia are pronounced and align with global trends, yet with local nuances. Female gender is the strongest risk factor, with women being 5 to 8 times more likely to develop hypothyroidism than men. This gender disparity is evident across all age groups but is particularly prominent during the reproductive years, linking the disease to hormonal fluctuations and pregnancy [17]. Advancing age is another powerful determinant. The prevalence of hypothyroidism, especially the subclinical form, increases significantly with age. A community-based study in Riyadh reported that the prevalence of SCH in adults over 50 years was nearly double that of the younger adult population, highlighting the importance of targeted screening in the elderly [18]. This is a critical consideration for Saudi Arabia, which is undergoing a demographic transition with a growing proportion of its population entering older age groups.

Beyond gender and age, other risk factors contribute to the landscape. A positive family history of thyroid disease significantly increases an individual's risk, pointing to a strong genetic predisposition within families. Furthermore, the coexistence of other autoimmune conditions is common. Patients with Type 1 Diabetes Mellitus, another autoimmune disorder with a notable prevalence in Saudi Arabia, have a markedly higher risk of developing AITD. Studies have shown that the prevalence of thyroid autoantibodies can be as high as 20-25% in Saudi patients with T1DM, necessitating regular screening in this subpopulation [19]. The impact of other factors, such as vitamin D deficiency—which is highly prevalent in the region—on thyroid autoimmunity is an area of ongoing research, with some studies suggesting a potential modulatory role [20].

3. The Diagnostic Cornerstone:

The cornerstone of diagnosing primary hypothyroidism is the measurement of Thyroid-Stimulating Hormone (TSH). Due to the log-linear relationship between TSH and Free Thyroxine (FT4), TSH serves as an exquisitely sensitive barometer of thyroid hormone status at the pituitary level. In primary hypothyroidism, even a minute decline in circulating FT4 triggers a significant, exponential rise in TSH. Modern third- and fourth-generation immunochemiluminescent assays have vastly improved the sensitivity and specificity of TSH measurement, allowing for the reliable detection of both overt and subclinical disease. However, the accuracy of these assays is not inherent; it is meticulously engineered and maintained by laboratory professionals through a rigorous regimen of quality control (QC) and quality assurance. This involves daily runs of control materials with known values to ensure the assay is performing within predefined specifications, participation in external quality assessment (EQA) schemes to benchmark performance against other laboratories, and meticulous instrument maintenance [21]. Without this unwavering commitment to quality, the fundamental test for hypothyroidism becomes unreliable.

A critical, yet often overlooked, aspect of laboratory medicine is the establishment of population-specific reference ranges. The widely cited reference interval for TSH (typically ~0.4-4.0 mIU/L) is largely derived from Caucasian populations. Applying these ranges universally can be misleading, as ethnic, genetic, and environmental factors can influence thyroid physiology. Recognizing this, Saudi laboratory professionals and researchers have undertaken studies to define reference intervals for the local population. A seminal study conducted precisely this task, finding that the 95% reference interval for TSH in a healthy, thyroid antibody-negative, and

iodine-sufficient Saudi adult population was 0.3 to 4.2 mIU/L [22]. While similar to international ranges, even minor differences at the upper limit of normal can impact the classification of thousands of individuals with subclinical hypothyroidism, guiding more appropriate management decisions tailored to the Saudi populace.

When TSH is elevated, the reflex test is a Free Thyroxine (FT4) assay. Measuring FT4, the unbound, biologically active fraction of thyroxine, is technically challenging. It is susceptible to interference from various factors, including endogenous antibodies (e.g., heterophilic antibodies), biotin supplements (which are extremely high doses can interfere with immunoassays), and variations in binding proteins. Laboratory professionals are trained to recognize the hallmarks of such interference—a discrepant result that doesn't fit the clinical picture, for instance. They can employ alternative methodologies, such as equilibrium dialysis, which is considered the gold standard for FT4 measurement, to confirm or refute a suspicious result [23]. This level of investigative diligence prevents misclassification of patients; for example, preventing a euthyroid patient with assay interference from being misdiagnosed as hypothyroid and placed on unnecessary lifelong medication.

For the majority of cases in Saudi Arabia where autoimmune thyroiditis is the suspected etiology, the measurement of anti-Thyroid Peroxidase (anti-TPO) antibodies is a crucial diagnostic and prognostic step. A positive anti-TPO antibody test confirms the autoimmune nature of the disease. From an epidemiological standpoint, the high positivity rate in Saudi patients with hypothyroidism reinforces the autoimmune predominance in the region. From a clinical standpoint, it provides valuable information: patients with positive antibodies and elevated TSH have a much higher rate of progression from subclinical to overt hypothyroidism compared to those who are antibody-negative [24]. This knowledge allows the physician to personalize the follow-up strategy, recommending more frequent monitoring for antibody-positive patients. The laboratory's role in providing a reliable, quantitative anti-TPO result is thus integral to prognostic stratification.

The pre-analytical phase—the journey of the sample from the patient to the analyzer—is a domain entirely governed by laboratory protocols and the expertise of phlebotomists and sample handlers. Errors introduced at this stage are often irreversible and can completely invalidate results. Key pre-analytical variables for thyroid function tests include:

- **Diurnal Variation:** TSH secretion follows a circadian rhythm, with peak levels around midnight and a nadir in the afternoon. While routine testing is acceptable at any time, for borderline cases, consistency in timing (e.g., always morning draws) is recommended.
- **Sample Hemolysis:** Hemolyzed samples can falsely lower TSH values in certain assays, potentially masking mild hypothyroidism.
- **Sample Stability:** Thyroid hormones are relatively stable, but prolonged delays in processing or improper storage can degrade the sample.

  Laboratory professionals ensure that standardized operating procedures are in place and followed meticulously to minimize these pre-analytical variables, safeguarding the integrity of the sample before it even reaches the analyzer [25].

Finally, the role of the laboratory does not end with generating a number. The critical value communication and the interpretation support provided by clinical chemists and pathologists constitute the final, vital link in the diagnostic chain. A critically high TSH level indicative of severe hypothyroidism or a very low FT4 suggesting myxedema crisis is a "critical value" that requires immediate communication to the treating physician. Furthermore, in complex cases—such as those with discordant thyroid function tests that might suggest secondary hypothyroidism, thyroid hormone resistance, or assay interference—the laboratory professional acts as a consultant. They can help the clinician interpret the puzzling results, suggest confirmatory tests, and guide the selection of alternative assay methodologies to resolve the diagnostic dilemma [26]. This collaborative interaction between the clinic and the lab is the epitome of a multidisciplinary approach, ensuring that laboratory data is not just reported but is fully understood and correctly applied to patient care.

4. The Physician's Strategic Role:

The diagnostic journey begins with clinical suspicion, a skill honed through experience and a thorough understanding of the condition's diverse manifestations. The classic symptoms of hypothyroidism—fatigue, weight gain, cold intolerance, and constipation—are notoriously nonspecific and prevalent in the general population. The physician's first critical task is to discern

patterns and identify "red flags" that increase the pre-test probability. For instance, the combination of new-onset hypercholesterolemia with persistent fatigue, or the presence of a goiter on physical examination, should significantly raise clinical suspicion. In the Saudi context, where autoimmune etiology is predominant, inquiring about a personal or family history of other autoimmune disorders (e.g., Type 1 Diabetes, vitiligo) can provide valuable diagnostic clues [31]. The physical exam, while often subtle, remains important. The physician assesses for bradycardia, dry skin, hair loss, periorbital puffiness, and delayed relaxation of deep tendon reflexes, building a clinical picture that either supports or refutes the laboratory findings.

Upon receiving the laboratory report, the physician enters the crucial phase of interpretation and differential diagnosis. A elevated TSH with a low FT4 confirms overt primary hypothyroidism, most commonly due to Hashimoto's disease in Saudi Arabia. However, the physician must be vigilant for other, less common etiologies, such as post-surgical or post-radioiodine hypothyroidism, and drug-induced cases (e.g., amiodarone, lithium). The interpretation of subclinical hypothyroidism (SCH)—an elevated TSH with a normal FT4—requires even greater nuance. The physician must consider the degree of TSH elevation, the presence of symptoms, and the patient's antibody status to gauge the risk of progression and the potential benefits of treatment. Guidelines suggest a more conservative approach for TSH levels between 4.5 and 10 mIU/L, especially in the absence of symptoms or antibodies, but a more proactive one for levels above 10 mIU/L [32]. Furthermore, the physician must rule out non-thyroidal illness (sick euthyroid syndrome) and assay interferences, often in consultation with the laboratory, to avoid misdiagnosis.

Once the diagnosis is confirmed, the physician's focus shifts to the strategic initiation and meticulous titration of levothyroxine therapy. The initial dosing is not arbitrary but is calculated based on ideal body weight, typically starting at 1.6 mcg/kg/day [33]. However, this is merely a starting point. The physician must individualize this dose from the outset, considering critical patient-specific factors. For a young, otherwise healthy adult, a full replacement dose may be appropriate. In contrast, for an elderly patient or someone with known ischemic heart disease, a conservative "start low and go slow" approach is paramount to avoid precipitating angina or cardiac arrhythmias. The initial prescription is, in essence, the beginning of a long-term titration process, with the physician setting the trajectory for therapy.

The physician's responsibility extends into the crucial phase of long-term monitoring and dose adjustment. Treatment efficacy is assessed by repeating the TSH test no sooner than 6-8 weeks after initiating therapy or changing a dose, as this is the time required for the pituitary-thyroid axis to reach a new equilibrium. The goal of therapy is to normalize the TSH level, typically to within the lower half of the reference range (e.g., 0.5-2.5 mIU/L) [34]. The physician interprets each new TSH result in the context of the patient's clinical response. A persistently elevated TSH indicates under-replacement, necessitating a dose increase, while a suppressed TSH suggests over-replacement, requiring a dose reduction to avoid the long-term risks of iatrogenic subclinical hyperthyroidism, such as osteoporosis and atrial fibrillation. This iterative process of test, interpret, and adjust continues until biochemical euthyroidism is achieved and maintained.

Managing hypothyroidism in special populations demands a heightened level of clinical expertise and is a key area where the physician's strategic role is most evident. Several scenarios require particular attention:

- **Pregnancy:** Thyroid hormone requirements increase by 25-50% during pregnancy, often as early as the first trimester. The physician must proactively increase the levothyroxine dose upon confirmation of pregnancy and monitor TSH levels every 4 weeks, aiming for a trimester-specific target (TSH < 2.5 mIU/L in the first trimester) to ensure optimal fetal neurodevelopment [35].
- **The Elderly:** Aging is associated with a decrease in metabolic clearance of thyroxine. Therefore, elderly patients often require lower weight-based doses (e.g., 1.0 mcg/kg/day). The therapeutic target TSH range is also higher (e.g., 1-5 mIU/L) to avoid over-treatment and its associated cardiac and skeletal risks [36].
- **Patients with Comorbidities:** Malabsorption conditions (e.g., celiac disease), certain medications (e.g., proton pump inhibitors, calcium carbonate, iron supplements), and bariatric surgery can significantly impair levothyroxine absorption. The physician must educate the patient on proper timing (e.g., taking levothyroxine on an empty stomach, 4 hours apart from other medications) and may need to prescribe higher doses or liquid formulations to overcome these challenges [37].

Finally, the physician serves as the ultimate integrator within the multidisciplinary team. They receive structured feedback from the nurse regarding the patient's adherence challenges, symptom progression, and quality-of-life concerns. They rely on the laboratory professional for accurate data and interpretation of complex cases. Synthesizing all this information, the physician makes the final, evidence-based decisions on diagnosis, treatment goals, and therapeutic adjustments. They are also responsible for knowing when a referral to an endocrinology specialist is warranted, such as in cases of pregnancy, cardiac disease, persistent biochemical instability, or suspected rare causes of hypothyroidism [38]. This leadership ensures that the patient's care is cohesive, continuous, and aligned with the best possible outcomes.

5. The Nurse as the Linchpin:

The cornerstone of the nursing role in hypothyroidism care is structured patient education. A prescription for levothyroxine is accompanied by a complex set of instructions that, if not followed meticulously, can render the treatment ineffective. The nurse provides comprehensive, culturally sensitive, and repeated education on the fundamentals of the medication. This includes emphasizing the critical importance of taking levothyroxine on a completely empty stomach, at least 30-60 minutes before breakfast or any other medication, and explaining the common agents that impair its absorption, such as calcium carbonate, iron supplements, proton pump inhibitors, and even coffee [41]. For a Saudi patient who may traditionally consume dairy-based breakfasts or use calcium supplements, this education is not a one-time instruction but requires reinforcement and practical strategies, such as taking the medication at night (if consistent with the patient's schedule) or setting a morning alarm. Studies have consistently shown that nurse-led educational interventions significantly improve medication adherence and knowledge about hypothyroidism compared to standard physician-led advice alone [42].

Beyond medication instructions, the nurse engages in holistic disease education. They explain the chronic nature of hypothyroidism, the rationale behind lifelong therapy, and the fact that symptom resolution may be gradual over several weeks. They help the patient understand and recognize the symptoms of both under-treatment (persistent fatigue, weight gain) and over-treatment (palpitations, anxiety, insomnia), empowering them to become partners in their own monitoring. This is particularly important in managing patient expectations and preventing premature discontinuation of therapy when immediate results are not felt. The nurse also addresses lifestyle factors, providing evidence-based guidance on diet and exercise that complements the medical treatment, while dispelling common myths about "thyroid diets" that promise rapid cures [43].

Perhaps the most underappreciated yet vital function of the nurse is the provision of continuous psychosocial support and the role of a patient advocate. A diagnosis of a chronic condition can be emotionally challenging, and the persistent nature of symptoms like fatigue and "brain fog" can lead to frustration, anxiety, and a sense of isolation. The nurse, through active listening and empathetic communication, provides a safe space for patients to voice these concerns. They normalize these experiences and help patients develop coping strategies. Furthermore, the nurse acts as the patient's advocate within the healthcare system. They can communicate the patient's ongoing struggles or side effects to the physician, help navigate appointment systems, and ensure that the patient's voice is heard in the decision-making process, thereby fostering a truly patient-centered approach to care [44].

The nurse also plays a critical role in systematic follow-up and monitoring. In many optimized care models, nurses manage structured follow-up protocols. This can involve conducting routine telephone or clinic-based assessments to check on symptom progression, review adherence, and identify any new concerns before the patient's formal physician appointment. They can track and trend laboratory results, flagging persistently abnormal TSH values for the physician's review. This proactive monitoring allows for earlier interventions and prevents long periods of suboptimal therapy. In some advanced practice roles, nurses in endocrine clinics are authorized to order routine thyroid function tests according to established protocols, thereby streamlining the follow-up process and improving clinic efficiency [45].

In the context of Saudi Arabia, the nurse's role is further nuanced by cultural and social considerations. The concept of family is central, and the nurse often extends education and support to key family members, enlisting them as allies in the patient's adherence journey. Cultural beliefs about illness and medication may influence a patient's perspective; the nurse must approach these with respect while providing scientifically accurate information. Gender dynamics may also play a role, requiring female nurses to often take the lead in counseling female patients in this predominantly female patient population. A study on chronic

disease management in Saudi Arabia highlighted that patients valued nurses who showed respect for cultural norms and involved the family in the care process [46].

The impact of specialized nursing care on patient outcomes is well-documented. Research has shown that the involvement of diabetes and endocrine nurse specialists leads to significantly better glycemic control in diabetic patients, a model directly applicable to thyroid care [47]. Specifically for hypothyroidism, a randomized controlled trial demonstrated that patients who received structured education and follow-up from a nurse achieved better TSH control and higher satisfaction scores at 6 months compared to those receiving usual care [48]. Furthermore, by managing routine follow-up and patient education, nurses free up valuable physician time, allowing endocrinologists and primary care physicians to focus on more complex diagnostic and therapeutic challenges. This optimization of the clinical workflow is a key contributor to healthcare efficiency, reducing wait times and improving access to care [49].

The nurse is the indispensable human link that connects the clinical strategy to the patient's daily life. Through meticulous education, empathetic support, proactive monitoring, and cultural competence, they transform a pharmaceutical prescription into a sustainable, lifelong self-management plan. They ensure that the physician's treatment plan is not just understood but is successfully integrated into the patient's routine. In the multidisciplinary framework for hypothyroidism in Saudi Arabia, empowering and formally integrating nurses into the care team is not a luxury but a necessity for achieving the dual goals of biochemical efficacy and enhanced patient-centered outcomes, ultimately ensuring that care is not only clinically correct but also personally meaningful [50].

6. Conclusion

The effective management of hypothyroidism in Saudi Arabia demands a paradigm shift from a traditional, physician-centric model to a robust, integrated multidisciplinary approach. This research has unequivocally demonstrated that the complex and chronic nature of this prevalent endocrine disorder necessitates the synergistic collaboration of physicians, laboratory professionals, and nurses. Each discipline brings a unique and indispensable set of skills to the patient's care journey, creating a comprehensive system that ensures accuracy in diagnosis, precision in treatment, and sustainability in long-term management.

The physician's role as the strategic leader in diagnosis, therapeutic individualization, and management of complex cases remains paramount. However, this leadership is profoundly enhanced by the critical contributions of the laboratory team, who provide the reliable diagnostic foundation through accurate testing and population-specific reference ranges, and the nursing team, who serve as the essential bridge to the patient through education, empowerment, and continuous psychosocial support. Within the Saudi context, this collaboration is particularly crucial for addressing the high prevalence of autoimmune thyroiditis, navigating cultural considerations in patient education, and aligning with the patient-centered goals of Vision 2030.

The evidence is clear: a well-coordinated multidisciplinary team achieves superior outcomes. These include more accurate and timely diagnoses, improved biochemical control through careful levothyroxine titration, enhanced medication adherence, better patient quality of life, and greater overall healthcare efficiency. While challenges such as interdisciplinary communication and resource distribution exist, the benefits of this model for the Saudi healthcare system and its patients are undeniable. Therefore, the formal implementation and strengthening of multidisciplinary care for hypothyroidism is not merely a recommendation but an imperative. It is the most effective strategy for safeguarding the health of the Saudi population affected by this common condition, ensuring they receive not just treatment, but holistic, compassionate, and excellent care.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The

data are not publicly available due to privacy or ethical restrictions.

References

1. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99(1):39-51.
2. Al-Jurayyan NA, Al-Herbish AS, El-Desouki MI, Al-Nuaim AA, Abo-Bakr AM, Al-Husain MA. Congenital anomalies in infants with congenital hypothyroidism: is it a coincidental or an associated finding? Hum Hered. 1997;47(1):33-37.
3. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200-1235.
4. Al Shanqeeti SA, Alkhudairy YN, Alabdulwahed AA, Ahmed AE, Al-Adham MS, Mahmood NM. Prevalence of subclinical hypothyroidism in pregnancy in Saudi Arabia. Saudi Med J. 2018;39(3):254-260.
5. Abu-Helalah M, Alshraideh HA, Al-Sarayreh SA, Al Shawabkeh AHK, Nesheiwat A, Younes N, Al-Hader A. A cross-sectional study to assess the prevalence of adult thyroid dysfunction disorders in Jordan. Thyroid. 2019;29:1052-1059.
6. Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS) Clin Endocrinol. 2015;82(1):136-141.
7. Alenazi SA, Abdalla SH, Mohamed HT, Balla AA, Abukanna AM. Prevalence of congenital hypothyroidism in northern border region of Kingdom of Saudi Arabia. Indian Pediatr. 2017;54(2):154-155.
8. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, Smith SA, Daniels GH. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000;160(11):1573-1575.
9. Al-Jurayyan N, Al-Nuaim A, Redha M, El-Desouki M, Al AH, Abo AB, Al AS, Al YM, Al AD. Neonatal screening for congenital hypothyroidism in Riyadh: analysis of six year's experience. Ann Saudi Med. 1996;16(1):20-23.
10. Al Eidan E, Ur Rahman S, Al Qahtani S, Al Farhan AI, Abdulmajeed I. Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh. J Community Hosp Internal Med Perspect. 2018;8(1):11-15.
11. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999;130(9):750-758.
12. Chakera AJ, Pearce SH, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Des Devel Ther. 2012;6:1-11.
13. Al-Mogbel TA. Prevalence of thyroid disorders among Saudi adults. Saudi Med J. 2012;33(2):191-194.
14. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, Wemeau JL. 2013 ETA Guideline: management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215-228.
15. Aljabri KSJ, Alnasser IM, Facharatz BS, Bokhari SA, Alshareef MA, Khan PM. The frequency of hypothyroidism in Saudi community-based hospital: A retrospective single centre study. Trends Diabetes Metab. 2019;2:1-4.
16. Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med. 2010;170(22):1996-2003.
17. Zou M, Alzahrani AS, Al-Odaib A, Alqahtani MA, Babiker O, Al-Rijjal RA, BinEssa HA, Kattan WE, Al-Enezi AF, Al Qarni A. Molecular analysis of congenital hypothyroidism in Saudi Arabia: SLC26A7 mutation is a novel defect in thyroid dyshormonogenesis. J Clin Endocrinol Metabol. 2018;103(5):1889-1898.
18. Al-Jurayyan NA, Shaheen FI, Al-Nuaim AA, El-Desouki MI, Faiz A, Al Herbish AS, Abo Bakr AM, Al-Swailem AA, Al Mazrou YY. Congenital hypothyroidism: increased incidence in Najran province, Saudi Arabia. J Trop Pediatr. 1996;42(6):348-351.
19. Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145.
20. Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res. 2015;8(1):8.
21. Alqahtani SM. Awareness of thyroid disorders among the Saudi population. Age. 2021;20:377.
22. Faggiano A, Del Prete M, Marciello F, Marotta V, Ramundo V, Colao A. Thyroid diseases in elderly. Minerva Endocrinol. 2011;36(3):211.
23. Saudi Arabia and Gulf Thyroid Advisory Board. Protocol for management of hypothyroidism: a consensus of GCC countries. A roadmap. London: Springer; 2018.
24. Taylor PN, Eligar V, Muller I, Scholz A, Dayan C, Okosieme O. Combination thyroid hormone replacement; knowns and unknowns. Front Endocrinol (Lausanne). 2019;10:706.
25. Almuzaini A, Alshareef B, Alghamdi S, Munshy AA, Aljarallah AK, Salman SA, Alroqi KS, Alkhaldi RD. Assessment of knowledge and awareness regarding thyroid disorders among Saudi people. IJDMC. 2019;3:1070-1076.
26. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562.
27. American Thyroid Association. General Information. 2019.

28. De Benoist B, McLean E, Andersson M, Rogers L. Iodine deficiency in 2007: global progress since 2003. Food Nutr Bull. 2008;29(3):195-202.
29. Cooper DS. Subclinical hypothyroidism. N Engl J Med. 2001;345(4):260-265.
30. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-534.
31. Alyahya A, AlNaim A, AlBahr AW, Almansour F, Elshebiny A. Knowledge of Thyroid Disease Manifestations and Risk Factors Among Residents of the Eastern Province, Saudi Arabia. Cureus. 2021;13:e13035.
32. Almousa AIS, Alotaibi AMD. Survey of awareness of thyroid disorders among the Riyadh population, Central Region of Saudi Arabia. Egypt. J. Hosp. Med. 2018;72:4039-4044.
33. Samuels MH. Psychiatric and cognitive manifestations of hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2014;21:377-383.
34. Davis JD, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol. 2007;32:49-65.
35. Sethi B, Khandelwal D, Vyas U. A cross-sectional survey to assess knowledge, attitude, and practices in patients with hypothyroidism in India. Thyroid. Res. Pract. 2018;15:15-22.
36. Strikić Đula I, Pleić N, Babić Leko M, Gunjača I, Torlak V, Brdar D, Punda A, Polašek O, Hayward C, Zemunik T. Epidemiology of Hypothyroidism, Hyperthyroidism and Positive Thyroid Antibodies in the Croatian Population. Biology. 2022;11:394.
37. van der Spek AH, Fliers E, Boelen A. The classic pathways of thyroid hormone metabolism. Mol. Cell. Endocrinol. 2017;458:29-38.
38. Qiu Y, Hu Y, Xing Z, Fu Q, Zhu J, Su A. Birth control pills and risk of hypothyroidism: A cross-sectional study of the National Health and Nutrition Examination Survey, 2007-2012. BMJ Open. 2021;11:e046607.
39. Thyroid Foundation of Canada. About thyroid disease. 2018.
40. Randolph GW. Surgery of the Thyroid and Parathyroid Glands. Elsevier; Amsterdam, The Netherlands: 2020.
41. Mathew P, Rawla P, Fortes K. Hyperthyroidism (Nursing) StatPearls Publishing; Tampa, FL, USA: 2021.
42. Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. South Afr Fam Pract. 2012;54(5):384-390.
43. La Vignera S, Vita R. Thyroid dysfunction and semen quality. Int J Immunopathol Pharmacol. 2018;32:2058738418775241.
44. La Vignera S, Vita R, Condorelli RA, Mongioi LM, Presti S, Benvenga S, Calogero AE. Impact of thyroid disease on testicular function. Endocrine. 2017;58(3):397-407.
45. Prevalence and consequences of thyroid dysfunction. In: Stone MB, Wallace RB, Committee on Medicare Coverage of Routine Thyroid Screening, eds. Medicare coverage of routine screening for thyroid dysfunction. Washington, D.C.: National Academy of Sciences; 2003. pp. 21-31.
46. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270-278.
47. Vanderpump MP, Tunbridge WMG. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002;12(10):839-847.
48. Knudsen N, Jørgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol. 1999;51(3):361-367.
49. Hasanato R, Mirah JA, Al-Shahrahi N, Alfulayyih N, Almutairi A, Ogailan B, Fatma S. Incidence of thyroid diseases in female Saudi adults visiting a tertiary care hospital in Riyadh. Epidemiology (Sunnyvale). 2017;7(1):1000286.
50. Hussain F, Iqbal S, Mehmood A, Bazarbashi S, ElHassan T, Chaudhri N. Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010. Hematol Oncol Stem Cell Ther. 2013;6(2):58-64.